Status:
COMPLETED
Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin
Lead Sponsor:
University of California, San Francisco
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. Previously, we have recruited a cohort of healthy volunteers (Studie...
Detailed Description
Detailed description pending
Eligibility Criteria
Inclusion
- Subjects must have previously participated in the "SOPHIE" study.
- Subjects will be between the ages of 18 and 40 years old
- Subjects will have been selected as healthy by medical history questionnaire and screening blood work (CBC, Comprehensive Metabolic panel).
- Subjects will be taking no regular medications and will have normal renal function.
Exclusion
- Pregnant
- Have a new history indicating they are no longer healthy; Individuals with anemia (hemoglobin \< 12 g/dL), an elevation in liver enzymes to higher than double the respective normal value, or elevated creatinine concentrations (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL), will be excluded.
- Taking a medication that could confound study results
- Do not consent to participate in the study.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00187707
Start Date
September 1 2005
End Date
August 1 2008
Last Update
August 9 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco General Hospital
San Francisco, California, United States, 94143